Ardea Biosciences (RDEA +6%) is trading higher after saying earlier that it's completed its end-of-phase 2 meetings with the FDA, and has reached an agreement on key aspects of its proposed lesinurad development plan for phase 3.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs